{"filing":{"accession_number":"0001193125-26-314214","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"d143170d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000119312526314214/d143170d8k.htm"},"events":[{"id":20137,"run_id":18127,"accession_number":"0001193125-26-314214","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Summit Therapeutics entered into an at-the-market (ATM) distribution agreement with J.P. Morgan Securities to offer and sell up to $380 million in common stock shares. This is a dilutive equity issuance structured as an ATM offering under Rule 415(a)(4), which allows the company to raise capital by selling shares at prevailing market prices. The magnitude ($380M) and structure (unregistered equity sales through a sales agent) are material to investors assessing capital structure and shareholder dilution.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19426,"accession_number":"0001193125-26-314214","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Summit Therapeutics entered into an at-the-market (ATM) distribution agreement with J.P. Morgan Securities to offer and sell up to $380 million in common stock shares. This is a dilutive equity issuance structured as an ATM offering under Rule 415(a)(4), which allows the company to raise capital by selling shares at prevailing market prices. The magnitude ($380M) and structure (unregistered equity sales through a sales agent) are material to investors assessing capital structure and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:36:39.621986+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19426,"accession_number":"0001193125-26-314214","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Summit Therapeutics entered into an at-the-market (ATM) distribution agreement with J.P. Morgan Securities to offer and sell up to $380 million in common stock shares. This is a dilutive equity issuance structured as an ATM offering under Rule 415(a)(4), which allows the company to raise capital by selling shares at prevailing market prices. The magnitude ($380M) and structure (unregistered equity sales through a sales agent) are material to investors assessing capital structure and shareholder dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:36:39.621986+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-07-23"}]}